Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : and Vaccine Gets Approval

07/29/2021 | 11:06am EDT

The Medicines Control Authority of Zimbabwe has approved the use of the single-dose Johnson and Johnson Covid-19 vaccine in Zimbabwe.

The vaccine becomes the fifth to be approved for use in the country after the Chinese Sinopharm and Sinovac, the Russian Sputnik V and the Indian Covaxin.

MCAZ spokesperson Mr Shingirai Gwatidzo said the emergency use authorisation issued to the Ministry of Health and Child Care was subject to a number of considerations including ensuring an adequate cold storage capacity.

The Johnson and Johnson vaccine needs to be stored in a freezer at -25 degrees celcius to -15 degrees celcius but once removed from the freezer, it requires refrigeration at +2 degrees celcius to +8 degrees celcius.

Zimbabwe however, has no capacity to store the vaccines in the freezer as the available cold chain allows for storage at between 2degrees and 8 degrees celcius.

"MCAZ reviewed the technical documentation and clinical studies conducted and issued Emergency Use Authorisation for Ministry of Health and Child Care to consider adding to the vaccines for use in Zimbabwe.

"This EUA is subject to a number of considerations which include ensuring there is adequate cold storage capacity to store the vaccines and also ensuring there is robust side effect monitoring in place to monitor for potential side effects," said Mr Gwatidzo.

He said the Ministry of Health would then decide whether to deploy the vaccines in Zimbabwe or not.

"Our responsibility is to ensure that we conduct the risk-benefit analysis prior to issuance of the EUA," he said.

The Johnson and Johnson vaccine is also being used in the South African inoculation drive.

Copyright The Herald. Distributed by AllAfrica Global Media (allAfrica.com)., source News Service English

All news about JOHNSON & JOHNSON
09/22JOHNSON & JOHNSON : Unit Signs Deal for HealthVerity Patient Data Platform
MT
09/22PRO BANKRUPTCY BRIEFING : J&J Beats Injury Lawyers on Talc Bankruptcy; Judge Questions Tal..
DJ
09/21JOHNSON & JOHNSON : Unit Collaborates With Persephone Biosciences On Stool Analysis
MT
09/21Shangula Rages Against West's Vaccine Nationalism
AQ
09/21Johnson & Johnson Data Shows COVID-19 Booster Shots 94% Effective Against Moderate to S..
MT
09/21Today on Wall Street: Markets at a pivot point
09/21JOHNSON & JOHNSON : Says New Data Show Booster Shot Increases COVID-19 Protection
MT
09/21J&J : Booster dose of its COVID shot prompts strong response
AQ
09/21JOHNSON & JOHNSON : Says New Data Shows a Booster of its One-Shot Vaccine Increases COVID-..
MT
09/21JOHNSON & JOHNSON : Announces Real-World Evidence and Phase 3 Data Confirming Strong and L..
PR
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 407 M - -
Net income 2021 22 809 M - -
Net Debt 2021 1 880 M - -
P/E ratio 2021 19,0x
Yield 2021 2,54%
Capitalization 432 B 432 B -
EV / Sales 2021 4,59x
EV / Sales 2022 4,38x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 163,93 $
Average target price 185,83 $
Spread / Average Target 13,4%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.16%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.32%246 414
NOVO NORDISK A/S50.62%232 291
ELI LILLY AND COMPANY35.22%206 972
ABBVIE INC.-0.69%188 045